Etofylline Clofibrate

益多酯

Report date: 2022/01/17 12:14:22

Base Information

Drug NameEtofylline Clofibrate
Drug Alias NameEtofyllini Clofibratis多利平酯Etofylline Ceofibrate特调酯祛酯酸乙羟茶碱
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator-activated receptor α agonists
TargetsPeroxisome proliferator-activated receptor α
Therapy Area/IndicationsHypercholesterolemia
Global Approved IndicationsHypercholesterolemia
Approved Indications in ChinaHypercholesterolemia
Original Approved Country/TerritoryMainland China
Original Approved Date1995/01/01
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesCspc Ouyi Pharmaceutical Co LtdShanghai Hengshan Pharmaceutical Co LtdShanghai Xinyi Vientiane Pharmaceutical Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsHypercholesterolemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A